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Abstract
Liver metastases develop in approximately half of women with metastatic breast cancer, and are typically associated with
metastases at other sites, indicating advanced disease and poor prognosis. Whenever possible, hormonal therapy should be
administered, until resistance develops. Several series in the literature have reported a poor effect of chemotherapy alone in
patients with metastatic breast cancer, therefore liver surgery could be considered as an adjuvant treatment to systemic
therapy in highly selected patients. This study looked at recent case series in the literature, and analysed prognostic factors
and indications for surgery.
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Background
Liver metastases (LMs) develop in approximately half
of women with metastatic breast cancer (MBC), and
are typically associated with metastases at other sites,
indicating advanced disease and poor prognosis [1].
Isolated LMs appear in only 4/5% of patients with
MBC [2/4]. Systemic chemotherapy or hormone
therapy (or both) is usually indicated for these
patients.
The standard approach to patients with newly
diagnosed MBC is to determine the extent of the
metastatic disease and whether there are sites of
disease that require urgent treatment. After this initial
evaluation, the key question for the clinician is
whether the patient is likely to benefit from hormonal
therapy. Whenever possible, hormonal therapy should
be administered, until resistance develops [5]. Several
series in the literature have reported a poor effect of
chemotherapy alone in patients with MBC [4,6,7].
Currently, with the recent chemotherapy regimen, the
median survival of such patients is close to 24 months
[8].
Because complete response of LM to chemotherapy
or hormone therapy is very rare, liver surgery could
be considered as an adjuvant treatment to systemic
therapy in highly selected patients. Publications
concerning surgery for breast LMs remain anec-
dotal and this surgery is still controversial because
the presence of LMs reflects the presence of dissemi-
nated disease, in which a local treatment modality is
of doubtful value [6]. In fact, this is true for any
metastatic tumour, notably for colorectal LM, for
which hepatectomy has clear indications.
Improvements in surgery and anaesthesiology, re-
sulting in a reduction of mortality and morbidity, have
allowed extension of the indications for hepatic
resection [9,10], and the first series reporting hepa-
tectomy for breast cancer patients was published in
1991 [3].
Results
Does liver resection result in an increase in survival?
Clearly the answer is yes in selected patients [11].
Series reported in the literature show (when consider-
ing only the series reporting at least 10 patients)
favourable 5-year overall survival rates ranging from
18% to 61% and a median overall survival reaching
57 months for curative resection (Table I) [1,11/18].
With classic non-operative treatment, there is no
living patient at 5 years.
Prognostic factors
Prognostic factors in MBC are difficult to validate
after liver resection owing to the small numbers of
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patients involved. Some authors report that the
interval between diagnosis of the primary cancer
and LM was statistically correlated with survival. So,
Pocard et al. [14] reported that survival at 36 months
was 55% when LM occurred in B/48 months versus
85% when LM occurred after 48 months (p/ 0.01),
and found that it was the only parameter statistically
correlated with survival. Elias et al. [11] found
that the only significant prognostic factor for survival
was the hormone receptor status, with a median
survival of 44 months when positive and 19 months
when negative (p/0.01). The hormone receptor
status is classically one of the main prognostic factors
in any study concerning survival of patients
with breast cancer. In the report by Sakamoto
et al. [18], the presence of extrahepatic disease prior
to hepatectomy was the only significant prognostic
factor and the 5-year survival rate of the patients
without extrahepatic disease was 31% versus 21%
(p/0.027).
It is fundamental to underline that in none of these
series, neither the extent of the liver disease (the
number and the maximal size of the LM), nor the
presence of positive hilar lymph nodes (present in
33% of the cases) [11], had a significant prognostic
impact on overall survival. This suggests that hepa-
tectomy for LM is only a cytoreductive surgery, and
cannot be considered as a definitive and isolated
treatment.
Indications
Definitive conclusions cannot be drawn because of
the limited and selected number of cases of these
series; however, this approach represents a valid
cytoreductive procedure for many patients with
isolated LM and may be curative for some of them.
Only a prospective multicentric randomized study
will demonstrate definitively whether surgical resec-
tion can really improve long-term survival rates in
patients with isolated LM with or without systemic
chemotherapy, compared with other methods of
treatment.
At this time, it appears useful and logical to propose
hepatectomy for women with MBC when the
three following conditions are absolutely confirmed:
(1) a low operative risk (this contraindicates a
complex and risky hepatectomy), (2) the LM is
completely resectable (this cytoreductive surgery
must be maximal and supraradical), (3) no extra-
hepatic disease (except for bone metastases which
are easily controlled with radiotherapy) [14]. The
decision is straightforward for young women. For
older women, the negative hormone receptor status
acts as a relative contraindication to hepatectomy
[11].
Moreover, new systemic treatment will proba-
bly modify this scheme and must be tested in
association with hepatectomy. In fact the general
landscape of endocrine therapy and chemother-
apy has recently been modified by the adjunct
of new potent drugs (last generation of aroma-
tase inhibitors, taxanes, herceptin), leading to
new therapeutic schemes in metastatic breast cancer
[5].
In conclusion, the surgical treatment of LM must
be considered as one part of a multimodal treatment
of the metastatic disease. It is of real benefit for a few
patients, and should be used more extensively in the
future.
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